Campbell 2022.

Study name	Reducing risk of dementia through deprescribing (R2D2)
Methods	Cluster‐randomised trial, with randomisation at the level of physicians. Physicians agreeing to participate in the trial will be randomised to intervention or usual care in blocks of 2 or 4. Physician randomisation status will determine participants' study group.
Participants	Primary care older adults with subjective cognitive decline or who make ≥ 1 error on a cognitive screening test, but do not have dementia, and are currently using a strong anticholinergic medication
Interventions	Intervention: deprescribing of target anticholinergics Control: usual care
Outcomes	Change in Cognitive Composite Score Change in Patient‐Reported Outcome Measurement Information System Change in Health Utilities Index
Starting date	20 July 2020
Contact information	campbenl@iu.edu
Notes